Elisha Tilton, MD
Ophthalmology · Longmont, CONPI 1518189869
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.7%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Genentech, Inc. accounts for 62.7% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2023 at $2,723 and has fallen 91.3% since, to $237 in 2025.
Across 71 payments — averaging $59.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$3K
- Eyepoint US, Inc.$269
- Apellis Pharmaceuticals, Inc.$208
- AbbVie$184
- Novartis$162
- Regeneron$144
- plus $601 from 14 others
Across 6 payments — averaging $8001.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$37K
- AbbVie$9K
- Alimera Sciences, Inc.$2K
What the payments were for
- Consulting fees$2,34556%
- Speaking & faculty fees$371%
- Food & beverage$1,81043%
- Entertainment$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 15 | $2,639 |
| Eyepoint US, Inc. | 3 | $269 |
| Apellis Pharmaceuticals, Inc. | 9 | $208 |
| AbbVie(2 entities) | 11 | $184 |
| Novartis | 4 | $162 |
| Regeneron | 2 | $144 |
| Alimera Sciences, Inc. | 6 | $113 |
| Astellas Pharma US Inc | 3 | $82 |
| Regeneron Healthcare Solutions, Inc. | 3 | $68 |
| Biogen | 3 | $56 |
| Rxsight Inc | 2 | $55 |
| Notal Vision, Inc. | 1 | $37 |
| Optos, Inc. | 2 | $37 |
| Alcon | 1 | $33 |
| Amgen | 1 | $27 |
| Bausch & Lomb Americas Inc. | 1 | $23 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $20 |
| Iridex Corporation | 1 | $18 |
| Eyevance Pharmaceuticals LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,208 in reported general payments places this provider in the 80th percentile of 262 ophthalmology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 127 | $7,250 |
| TobradexTobramycin/Dexamethasone | 19 | $5,797 |
| Difluprednate | 29 | $4,259 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 17 | $2,166 |
| Ketorolac Tromethamine | 58 | $1,556 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 44 | $369 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 26 | $351 |
| Latanoprost | 16 | $298 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 12 | $214 |
| Timolol Maleate | 17 | $172 |
| Brimonidine Tartrate | 19 | $161 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Longmont
- Mark PackerBoulder$3.5M
- Jon DishlerGreenwood Village$1M
- Mark DaceyDenver$370K
- Cristos IfantidesDenver$343K
- Geeta Lalchandani LalwaniBoulder$319K
- Richard DavidsonAurora$316K
- Steven DeweyColorado Springs$246K
- Jack ZamoraDenver$172K
- Eva KimDenver$95K
- Michael JansenDenver$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.